391 related articles for article (PubMed ID: 23843896)
1. Role of urokinase receptor in tumor progression and development.
Noh H; Hong S; Huang S
Theranostics; 2013; 3(7):487-95. PubMed ID: 23843896
[TBL] [Abstract][Full Text] [Related]
2. TGF-β2 promotes RPE cell invasion into a collagen gel by mediating urokinase-type plasminogen activator (uPA) expression.
Sugioka K; Kodama A; Okada K; Iwata M; Yoshida K; Kusaka S; Matsumoto C; Kaji H; Shimomura Y
Exp Eye Res; 2013 Oct; 115():13-21. PubMed ID: 23810810
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of uPAR promotes urokinase translocation into the nucleus and epithelial to mesenchymal transition in neuroblastoma.
Semina EV; Rubina KA; Shmakova AA; Rysenkova KD; Klimovich PS; Aleksanrushkina NA; Sysoeva VY; Karagyaur MN; Tkachuk VA
J Cell Physiol; 2020 Sep; 235(9):6268-6286. PubMed ID: 31990070
[TBL] [Abstract][Full Text] [Related]
4. Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with beta1 integrins.
Tang CH; Hill ML; Brumwell AN; Chapman HA; Wei Y
J Cell Sci; 2008 Nov; 121(Pt 22):3747-56. PubMed ID: 18940913
[TBL] [Abstract][Full Text] [Related]
5. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
6. The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling.
Carriero MV; Stoppelli MP
Curr Pharm Des; 2011; 17(19):1944-61. PubMed ID: 21711235
[TBL] [Abstract][Full Text] [Related]
7. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
[TBL] [Abstract][Full Text] [Related]
8. A Cross Talk between Neuronal Urokinase-type Plasminogen Activator (uPA) and Astrocytic uPA Receptor (uPAR) Promotes Astrocytic Activation and Synaptic Recovery in the Ischemic Brain.
Diaz A; Merino P; Manrique LG; Ospina JP; Cheng L; Wu F; Jeanneret V; Yepes M
J Neurosci; 2017 Oct; 37(43):10310-10322. PubMed ID: 28931568
[TBL] [Abstract][Full Text] [Related]
9. Transforming Growth Factor-Beta and Urokinase Type Plasminogen Interplay in Cancer.
Santibanez JF; Krstic J
Curr Protein Pept Sci; 2018; 19(12):1155-1163. PubMed ID: 29086689
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of uPA/uPAR inhibits intermittent hypoxia-induced epithelial-mesenchymal transition (EMT) in DAOY and D283 medulloblastoma cells.
Gupta R; Chetty C; Bhoopathi P; Lakka S; Mohanam S; Rao JS; Dinh DE
Int J Oncol; 2011 Mar; 38(3):733-44. PubMed ID: 21181094
[TBL] [Abstract][Full Text] [Related]
11. Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand.
De Souza M; Matthews H; Lee JA; Ranson M; Kelso MJ
Bioorg Med Chem; 2011 Apr; 19(8):2549-56. PubMed ID: 21454081
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism.
Czekay RP; Loskutoff DJ
J Cell Physiol; 2009 Sep; 220(3):655-63. PubMed ID: 19472211
[TBL] [Abstract][Full Text] [Related]
13. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
14. Urokinase-type Plasminogen Activator (uPA) Binding to the uPA Receptor (uPAR) Promotes Axonal Regeneration in the Central Nervous System.
Merino P; Diaz A; Jeanneret V; Wu F; Torre E; Cheng L; Yepes M
J Biol Chem; 2017 Feb; 292(7):2741-2753. PubMed ID: 27986809
[TBL] [Abstract][Full Text] [Related]
15. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
[TBL] [Abstract][Full Text] [Related]
16. Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model.
Zhang J; Sud S; Mizutani K; Gyetko MR; Pienta KJ
Neoplasia; 2011 Jan; 13(1):23-30. PubMed ID: 21245937
[TBL] [Abstract][Full Text] [Related]
17. uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
Pavón MA; Arroyo-Solera I; Céspedes MV; Casanova I; León X; Mangues R
Oncotarget; 2016 Aug; 7(35):57351-57366. PubMed ID: 27385000
[TBL] [Abstract][Full Text] [Related]
18. ECRG2 regulates cell migration/invasion through urokinase-type plasmin activator receptor (uPAR)/beta1 integrin pathway.
Cheng X; Shen Z; Yin L; Lu SH; Cui Y
J Biol Chem; 2009 Nov; 284(45):30897-906. PubMed ID: 19717562
[TBL] [Abstract][Full Text] [Related]
19. The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target.
O'Halloran TV; Ahn R; Hankins P; Swindell E; Mazar AP
Theranostics; 2013; 3(7):496-506. PubMed ID: 23843897
[TBL] [Abstract][Full Text] [Related]
20. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration.
Yebra M; Parry GC; Strömblad S; Mackman N; Rosenberg S; Mueller BM; Cheresh DA
J Biol Chem; 1996 Nov; 271(46):29393-9. PubMed ID: 8910604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
